SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...

In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...

Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth ...

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...

BHUBANESWAR: In a significant medical breakthrough, India's first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be succ ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

San Sebastian, Gipuzkoa, Spain, December 4, 2024 - VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from ...

SAN SEBASTIAN, Spain, Dec. 4, 2024 /PRNewswire/ -- VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment ...